Stingray Bio secures investment from o2h Ventures to develop oncology drugs targeting the LMTK3 kinase pathway
The funding was provided by o2h Ventures to back the University of Sussex spin out.
Stingray Bio is a spin out from the University of Sussex developing small molecule inhibitors for cancer treatment. The company focuses on targeting the LMTK3 kinase signalling pathway.
Stingray Bio has secured investment from o2h Ventures to fund the development of novel small molecule inhibitors targeting the LMTK3 kinase signalling pathway for cancer treatment. The funding will advance the commercialisation of research originating from the University of Sussex.
The spin out is built on foundational work by University of Sussex professors Georgios Giamas and John Spencer. The capital will support the translation of preclinical validation towards clinical application.
From the founder
"By founding and building Stingray Bio alongside my colleague Professor John Spencer, we have taken a critical next step towards exploiting our new discoveries in LMTK3 kinase signalling for the benefit of cancer patients."
Georgios Giamas
Chief Scientific Advisor and Director at Stingray Bio
Investor perspective
"We are delighted to be working with the University of Sussex and the founders to launch and grow Stingray Bio. We have been following the science for several years and we are now excited to support the commercialisation of the founder's research to develop new drugs for cancer."
Sunil Shah
Co-Founder and Managing Partner, o2h
Use of funds
- 01Fund research and development
Investors
Categories
About the company
Stingray Bio
Stingray Bio develops small molecule inhibitors to target the LMTK3 kinase signalling pathway in cancer treatment.